Medication-induced fractures: Screening and treatment strategies
Medication-induced osteoporosis leads to substantial fracture morbidity. With polypharmacy and the aging population in the United States, significant increases in medication-associated fractures are predicted. The most common medication to cause osteoporosis and increase fractures is glucocorticoids...
Gespeichert in:
Veröffentlicht in: | The American journal of the medical sciences 2024-08 |
---|---|
Hauptverfasser: | , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | |
---|---|
container_issue | |
container_start_page | |
container_title | The American journal of the medical sciences |
container_volume | |
creator | Javed, Laraib Khakwani, Aemen Khan, Uzair Humphrey, Mary Beth |
description | Medication-induced osteoporosis leads to substantial fracture morbidity. With polypharmacy and the aging population in the United States, significant increases in medication-associated fractures are predicted. The most common medication to cause osteoporosis and increase fractures is glucocorticoids. Many other therapies, including loop diuretics, SGLT2 inhibitors, thiazolidinediones, proton pump inhibitors, selective serotonin reuptake inhibitors, heparin, warfarin, antiepileptics, aromatase inhibitors, anti-androgen therapies, gonadotropin-releasing hormone antagonists, and calcineurin inhibitors are associated with increased fracture risks. Here, we review the latest evidence for fracture risk for these medications and discuss fracture risk screening and management strategies. |
doi_str_mv | 10.1016/j.amjms.2024.08.024 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3099804504</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S000296292401440X</els_id><sourcerecordid>3099804504</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1548-f63c725c66092a9a14f30e6489368b1a94fc9a2461a77f4914c0ffeed7c35d633</originalsourceid><addsrcrecordid>eNp9kEtLxDAUhYMozjj6CwTp0k3rzaOZRBAU8QUjLtR1iOmNZJi2Y5IK_nuroy5dnc137uF-hBxSqChQebKsbLtsU8WAiQpUNcYWmdKaq5JpDdtkCgCs1JLpCdlLaQlAmaJ8l0y4ZlQwoabk_B6b4GwOfVeGrhkcNoWP1uUhYjotHl1E7EL3WtiuKXJEm1vscpFytBlfA6Z9suPtKuHBT87I8_XV0-VtuXi4ubu8WJSO1kKVXnI3Z7WTEjSz2lLhOaAUSnOpXqjVwjttmZDUzudeaCoceI_YzB2vG8n5jBxv7q5j_zZgyqYNyeFqZTvsh2Q4aK1A1CBGlG9QF_uUInqzjqG18cNQMF_qzNJ8qzNf6gwoM8bYOvoZGF5abP46v65G4GwD4Pjme8BokgvYjcZCRJdN04d_Bz4B1wd_-A</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3099804504</pqid></control><display><type>article</type><title>Medication-induced fractures: Screening and treatment strategies</title><source>Alma/SFX Local Collection</source><creator>Javed, Laraib ; Khakwani, Aemen ; Khan, Uzair ; Humphrey, Mary Beth</creator><creatorcontrib>Javed, Laraib ; Khakwani, Aemen ; Khan, Uzair ; Humphrey, Mary Beth</creatorcontrib><description>Medication-induced osteoporosis leads to substantial fracture morbidity. With polypharmacy and the aging population in the United States, significant increases in medication-associated fractures are predicted. The most common medication to cause osteoporosis and increase fractures is glucocorticoids. Many other therapies, including loop diuretics, SGLT2 inhibitors, thiazolidinediones, proton pump inhibitors, selective serotonin reuptake inhibitors, heparin, warfarin, antiepileptics, aromatase inhibitors, anti-androgen therapies, gonadotropin-releasing hormone antagonists, and calcineurin inhibitors are associated with increased fracture risks. Here, we review the latest evidence for fracture risk for these medications and discuss fracture risk screening and management strategies.</description><identifier>ISSN: 0002-9629</identifier><identifier>ISSN: 1538-2990</identifier><identifier>EISSN: 1538-2990</identifier><identifier>DOI: 10.1016/j.amjms.2024.08.024</identifier><identifier>PMID: 39214248</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Antiepileptics ; Fracture ; Glucocorticoids ; Osteoporosis ; Proton pump inhibitors</subject><ispartof>The American journal of the medical sciences, 2024-08</ispartof><rights>2024</rights><rights>Published by Elsevier Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c1548-f63c725c66092a9a14f30e6489368b1a94fc9a2461a77f4914c0ffeed7c35d633</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39214248$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Javed, Laraib</creatorcontrib><creatorcontrib>Khakwani, Aemen</creatorcontrib><creatorcontrib>Khan, Uzair</creatorcontrib><creatorcontrib>Humphrey, Mary Beth</creatorcontrib><title>Medication-induced fractures: Screening and treatment strategies</title><title>The American journal of the medical sciences</title><addtitle>Am J Med Sci</addtitle><description>Medication-induced osteoporosis leads to substantial fracture morbidity. With polypharmacy and the aging population in the United States, significant increases in medication-associated fractures are predicted. The most common medication to cause osteoporosis and increase fractures is glucocorticoids. Many other therapies, including loop diuretics, SGLT2 inhibitors, thiazolidinediones, proton pump inhibitors, selective serotonin reuptake inhibitors, heparin, warfarin, antiepileptics, aromatase inhibitors, anti-androgen therapies, gonadotropin-releasing hormone antagonists, and calcineurin inhibitors are associated with increased fracture risks. Here, we review the latest evidence for fracture risk for these medications and discuss fracture risk screening and management strategies.</description><subject>Antiepileptics</subject><subject>Fracture</subject><subject>Glucocorticoids</subject><subject>Osteoporosis</subject><subject>Proton pump inhibitors</subject><issn>0002-9629</issn><issn>1538-2990</issn><issn>1538-2990</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNp9kEtLxDAUhYMozjj6CwTp0k3rzaOZRBAU8QUjLtR1iOmNZJi2Y5IK_nuroy5dnc137uF-hBxSqChQebKsbLtsU8WAiQpUNcYWmdKaq5JpDdtkCgCs1JLpCdlLaQlAmaJ8l0y4ZlQwoabk_B6b4GwOfVeGrhkcNoWP1uUhYjotHl1E7EL3WtiuKXJEm1vscpFytBlfA6Z9suPtKuHBT87I8_XV0-VtuXi4ubu8WJSO1kKVXnI3Z7WTEjSz2lLhOaAUSnOpXqjVwjttmZDUzudeaCoceI_YzB2vG8n5jBxv7q5j_zZgyqYNyeFqZTvsh2Q4aK1A1CBGlG9QF_uUInqzjqG18cNQMF_qzNJ8qzNf6gwoM8bYOvoZGF5abP46v65G4GwD4Pjme8BokgvYjcZCRJdN04d_Bz4B1wd_-A</recordid><startdate>20240828</startdate><enddate>20240828</enddate><creator>Javed, Laraib</creator><creator>Khakwani, Aemen</creator><creator>Khan, Uzair</creator><creator>Humphrey, Mary Beth</creator><general>Elsevier Inc</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20240828</creationdate><title>Medication-induced fractures: Screening and treatment strategies</title><author>Javed, Laraib ; Khakwani, Aemen ; Khan, Uzair ; Humphrey, Mary Beth</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1548-f63c725c66092a9a14f30e6489368b1a94fc9a2461a77f4914c0ffeed7c35d633</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Antiepileptics</topic><topic>Fracture</topic><topic>Glucocorticoids</topic><topic>Osteoporosis</topic><topic>Proton pump inhibitors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Javed, Laraib</creatorcontrib><creatorcontrib>Khakwani, Aemen</creatorcontrib><creatorcontrib>Khan, Uzair</creatorcontrib><creatorcontrib>Humphrey, Mary Beth</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>The American journal of the medical sciences</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Javed, Laraib</au><au>Khakwani, Aemen</au><au>Khan, Uzair</au><au>Humphrey, Mary Beth</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Medication-induced fractures: Screening and treatment strategies</atitle><jtitle>The American journal of the medical sciences</jtitle><addtitle>Am J Med Sci</addtitle><date>2024-08-28</date><risdate>2024</risdate><issn>0002-9629</issn><issn>1538-2990</issn><eissn>1538-2990</eissn><abstract>Medication-induced osteoporosis leads to substantial fracture morbidity. With polypharmacy and the aging population in the United States, significant increases in medication-associated fractures are predicted. The most common medication to cause osteoporosis and increase fractures is glucocorticoids. Many other therapies, including loop diuretics, SGLT2 inhibitors, thiazolidinediones, proton pump inhibitors, selective serotonin reuptake inhibitors, heparin, warfarin, antiepileptics, aromatase inhibitors, anti-androgen therapies, gonadotropin-releasing hormone antagonists, and calcineurin inhibitors are associated with increased fracture risks. Here, we review the latest evidence for fracture risk for these medications and discuss fracture risk screening and management strategies.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>39214248</pmid><doi>10.1016/j.amjms.2024.08.024</doi></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0002-9629 |
ispartof | The American journal of the medical sciences, 2024-08 |
issn | 0002-9629 1538-2990 1538-2990 |
language | eng |
recordid | cdi_proquest_miscellaneous_3099804504 |
source | Alma/SFX Local Collection |
subjects | Antiepileptics Fracture Glucocorticoids Osteoporosis Proton pump inhibitors |
title | Medication-induced fractures: Screening and treatment strategies |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T22%3A08%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Medication-induced%20fractures:%20Screening%20and%20treatment%20strategies&rft.jtitle=The%20American%20journal%20of%20the%20medical%20sciences&rft.au=Javed,%20Laraib&rft.date=2024-08-28&rft.issn=0002-9629&rft.eissn=1538-2990&rft_id=info:doi/10.1016/j.amjms.2024.08.024&rft_dat=%3Cproquest_cross%3E3099804504%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3099804504&rft_id=info:pmid/39214248&rft_els_id=S000296292401440X&rfr_iscdi=true |